Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamise (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT) 40th Annual American Society of Slinical Oncology meeting. New Orleans, Louisiana USA June 2004

DW Hiller, L Earl, HM Dunn, Sarah Bathers, David Spooner, R Grieve, RK Agrawal

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)595S
JournalJournal of Clinical Oncology
Volume22 (14)
Publication statusPublished - 1 Jan 2007

Cite this